Aflibercept in Diabetic Retinopathy

Bheemidi, Abhinav R; Valentim, Carolina C S; Singh, Rishi P.

doi:10.17925/opht.2021.15.1.18

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ranibizumab (Lucentis ® , Novartis, Basel, Switzerland), the off-label bevacizumab (Avastin, Genentech, CA, USA), and aflibercept (Eylea, Regeneron, NY, USA) are the anti-VEGF agents from the “first-line treatment”. Aflibercept and ranibizumab have been approved by the United States Food and Drug Administration (FDA) [ 131 , 132 , 133 ]. Bevacizumab is a humanized monoclonal antibody that specifically binds to the VEGF-A protein [ 134 ].…”

Section: The Anti-angiogenic Modulatory Effect Of Resveratrolmentioning

confidence: 99%

Resveratrol: Its Path from Isolation to Therapeutic Action in Eye Diseases

et al. 2022

View full text Add to dashboard Cite

Due to the confirmed therapeutic potential of resveratrol (Rv) for eye diseases, namely its powerful anti-angiogenic and antioxidant effects, this molecule must be studied more deeply. Nowadays, the pharmaceutic and pharmacokinetic available studies offer a troubling picture because of its low stability and bioavailability. To overcome this problem, researchers started to design and create different delivery systems that could improve the delivery amount of Rv. Therefore, this review aims to shed light on the proper and efficient techniques to isolate, purify and quantify the Rv molecule, and how this therapeutic molecule can be a part of a delivery system. The Rv great impact on aspects regarding its stability, bioavailability and absorption are also debated here, based on the existent literature on in vitro and in vivo human and animal studies. Moreover, after its absorption the Rv influence at the molecular level in ocular pathologies is described. In addition, the present review summarizes the available literature about Rv, hoping that Rv will gain more attention to investigate its unexplored side.

show abstract